Related Experiment Video
Updated: Jan 8, 2026
12:34
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
1.2K
Latest Research Hot Spots of Atopic Dermatitis Management Using Janus Kinase Inhibitor: A Bibliometric Analysis and
Houriah Nukaly1, Deemah S AlHuraish2, Basel H Bakhamees3
1Division of Experimental Medicine, McGill University Health Centre, Montréal, Québec, Canada.
Clinical, Cosmetic and Investigational Dermatology
|December 19, 2025
Summary
This bibliometric review maps global research on Janus kinase inhibitors (JAKi) for atopic dermatitis (AD). It identifies key research hotspots, collaborations, and influential figures in JAKi-treated AD, highlighting upadacitinib and baricitinib.
Area of Science:
- Bibliometrics and scientometrics applied to dermatological research.
- Pharmacological research focusing on targeted therapies for inflammatory skin conditions.
Background:
- Atopic dermatitis (AD) is a prevalent skin condition affecting 5-20% globally.
- Moderate-to-severe AD often necessitates systemic treatments.
- Janus kinase inhibitors (JAKi) represent a significant advancement in AD therapy.
Purpose of the Study:
- To conduct a bibliometric and visualized review of global research on JAK inhibitors for atopic dermatitis.
- To identify research hotspots, collaboration networks, and influential contributors in this field.
- To analyze trends and emerging themes in JAKi-based AD research from 2014-2024.
Main Methods:
- Bibliometric analysis of publications from the Web of Science Core Collection (2014-2024).
- Search terms included "Janus kinase inhibitors" OR "JAK" AND "atopic dermatitis".
- Data visualization and analysis performed using VOSviewer, Excel, and Draw.io.
Main Results:
- The United States led publication output (34%), followed by Germany, Japan, and China.
- Key institutions included Icahn School of Medicine at Mount Sinai and Oregon Health & Science University.
- Prolific authors were Emma Guttman-Yassky and Eric Simpson; central keywords included "atopic dermatitis", "JAK inhibitors", "upadacitinib", and "baricitinib".
Conclusions:
- This review provides an updated overview of global research on JAK inhibitors for AD.
- It highlights key players, collaboration patterns, and emerging research areas like abrocitinib and biologics.
- Findings can inform future research directions and address knowledge gaps in targeted AD therapy.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
02:26NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
01:11Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
02:06Allergic Reactions
31.9K
Overview
31.9K
01:07MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K